...
"The inactivated vaccine we developed can cover all strains of the coronavirus that have been detected so far, including the virus strains tracked in the Xinfadi market in Beijing," Yang Xiaoming, president of China National Pharmaceutical Group (Sinopharm), noted in response to public concerns that the vaccine under the R&D process would be ineffective as the virus mutates.
The research team has carried out cross-protection experiments to test if the anti-serum obtained by immunizing animals can produce an immune response to different genotypes of strains of coronavirus, Yang said.
Sinopharm, whose COVID-19 inactivated vaccine candidates have been delivered into phase three clinical trials, have stored more than 4 million doses of the vaccines, the Global Times learned from the group.
Yang said that the group is currently storing more COVID-19 vaccines. Once a candidate is approved for the market, the company will soon be able to provide as many doses of vaccines as the country needs.
...